Home‎ > ‎

TB News and Announcements

Google Alerts for TB

RSS Feed from Twitter

The gadget spec URL could not be found

Lancet Special Series Examines TB Worldwide

posted May 30, 2010, 8:50 AM by USAID Tuberculosis   [ updated May 30, 2010, 10:09 AM ]

Tuberculosis and HIV patient Tana Tip, 33, attempting to sleep in the isolation ward at Wat Prabat Nampu in Lopburi, Thailand. Simple TB is simple to treat, a $10 course of medication, but the pills must be taken in specific combinations for six months to completely wipe out the bacteria. If treatment is stopped short, the TB learns to fight back against the drugs, mutating into a tougher strain for which few, if any, medications exist. It can cost $100,000 a year or more to cure drug-resistant TB, which is described as multi-drug-resistant (MDR), extremely drug-resistant (XDR) and completely drug-resistant (CDR).
Photograph by: David Longstreath

5/19/10 Kaiser News--The Lancet released on Wednesday a special series on tuberculosis, which includes a series of papers and comments highlighting the need for new tools, the threat posed by drug-resistant strains, results of current control efforts and other issues about TB worldwide, Agence France-Presse reports.

One article notes that global treatment strategies prevented six million deaths and successfully treated 36 million cases of the disease between 1995 and 2008 (5/18). "Yet tuberculosis remains a severe global public health threat. There are more than 9 million new cases every year worldwide ... Although the overall target related to the Millennium Development Goals of halting and beginning to reverse the epidemic might have already been reached in 2004, the more important long-term elimination target set for 2050 will not be met with present strategies and instruments," the authors of the study write (Lonnroth et al., 5/19).

The journal highlighted the gaps in funding required to improve TB control, AFP writes. At the launch of the report in Geneva, Mphu Ramatlapeng, Lesotho's health minister, remarked, "Tuberculosis is unfashionable these days." Researchers said, "Tuberculosis can no longer be the neglected sister of HIV and malaria," AFP reports.

One article warns that the absence of major investments in new technology and prevention and treatment tools could make drug-resistant strains of TB the "dominant" form of TB over the coming decades, according to the news service (5/18). The article notes "that India and China had around 50 percent of the global MDR-TB burden, followed by Russia with 9 percent," Reuters writes. The authors write, "The future possibility of strains that are totally resistant to all anti-tuberculosis drugs is not inconceivable."

"In other studies in the series ... scientists said the combined impact of new drugs, vaccines, and diagnostic tests could cut worldwide incidence of TB by 94 percent by 2050," the news service reports. According to experts, only about a quarter of the funding needed for drug research and development is available.

"Development of new drugs for TB is lengthy, expensive, and risky, and the expected revenues are too small to justify commercial investment," Zhenkun Ma of the Global Alliance for TB Drug Development and co-authors write in a paper. "New financing and market incentive mechanisms are needed."

The journal also notes that "there are 11 potential TB vaccines being tested in human trials and up to 10 experimental medicines in the TB drug 'pipeline.' Since many drugs fail in late-stage trials, this handful of possibilities is unlikely to be enough," Reuters reports (Kelland, 5/18).

The series also focused on the broader issues that contribute to the spread of TB, the Associated Press reports. "Experts said TB isn't only a medical problem, but is intertwined with poverty, as it spreads widely among people living in overcrowded, dirty places. They said TB programs need to go beyond health and include other sectors like housing, education and transportation," the news service writes. Philip Stevens, a health policy expert at the International Policy Network, said the disease "cannot be tackled in isolation," noting that the focus of control efforts should be on "economic growth, which is outside the control of the U.N." (Cheng, 5/18).

"In the eighth and final paper ... a call to action is made to a wide range of sectors to assist scale-up TB service delivery, research and control. The launch of The Lancet TB Observatory, which will monitor progress on key indicators on an ongoing basis, is also announced," according to a Lancet press release. The Observatory, which is a collaboration between the Lancet, the Stop TB Parternship, the WHO and the Global Fund to Fight AIDS, Tuberculosis, and Malaria, "will assess and monitor" TB research, financing and other information. In a comment discussing the Observatory, Lancet Editor-in-Chief Richard Horton and Executive Editor Pamela Das observe that currently "there is no formal mechanism to assess this information critically and independently. Nor is there any means to hold the various stakeholders in tuberculosis control to account" (5/18).

The series also includes comments about how to scale-up an integrated TB and HIV response, the burden of the disease in women and children and how migration patterns within and between countries contribute to the spread of TB. The Lancet Table of Contents is available here.

UN efforts to fight TB have flopped

posted May 30, 2010, 8:48 AM by USAID Tuberculosis

By MARIA CHENG (AP) – May 18, 2010

Global efforts to control tuberculosis have failed and radical new approaches are needed, experts said Wednesday.

With more than 9 million people infected last year, including 2 million deaths, officials say there is more tuberculosis now than at any other time in history. In a special tuberculosis edition of the British medical journal Lancet published on Wednesday, experts said past failures prove new strategies are required.

For years, the World Health Organization and partners have fought TB largely with a program where health workers watch patients take their drugs — even though the agency acknowledged in a 2008 report that this treatment program didn't significantly curb TB spread.

Experts said TB isn't only a medical problem, but is intertwined with poverty, as it spreads widely among people living in overcrowded, dirty places. They said TB programs need to go beyond health and include other sectors like housing, education and transportation.

Some officials questioned whether continued U.N. programs could even combat TB. "The main priority for TB control is improved living conditions and economic growth, which is outside the control of the U.N.," said Philip Stevens, a health policy expert at International Policy Network, a London-based think tank. "TB cannot be tackled in isolation."

Stevens said the global health community also needs to be more vigilant about the drugs they buy for TB programs. According to a 2007 report from the Global Fund to fight AIDS, Tuberculosis and Malaria, half of the drugs the fund bought for poor countries didn't comply with their own drug quality standards.

Dr. Mario Raviglione, head of WHO's TB department, said the recent fall in TB was "very minor" and that the agency was trying to understand how better to fight the epidemic.

Still, WHO said their basic TB programs cured more than 36 million people between 1995 and 2008, and saved up to 6 million from dying of the potentially fatal lung disease.

But the recent spread of drug-resistant TB illustrates there have been major shortcomings. Drug-resistant TB emerges when patients don't finish their pills or take substandard drugs — like many of those bought by the Global Fund.

One of the public health community's biggest failings in fighting drug-resistant TB is the lack of basic data. In a WHO report published in March, the agency said it didn't know whether the global outbreak of drug-resistant strains are getting bigger or smaller.

"It is surprising how much data we're lacking," said Pamela Das, executive editor at Lancet, who co-authored an accompanying commentary in the journal. "There are so many gaps that we don't really know what's going on."

One of the Lancet papers called for the disease to be eliminated by 2050, while another said WHO guidelines on treating people infected with both TB and AIDS were not based on good evidence and needed to be revised.

Das said WHO and partners should be proud of drop in TB cases, but that the agency has failed to achieve its mandate and those gains could soon be reversed. She doubted the disease could be wiped out by 2050 unless current strategies addressed the poverty underlying much of TB.

Multidrug and extensively drug-resistant TB (M/XDR-TB)

posted Mar 19, 2010, 9:58 AM by USAID Tuberculosis

This new report on anti-tuberculosis (TB) drug resistance
by the World Health Organization (WHO) updates
“Anti-tuberculosis drug resistance in the world: Report
No. 4” published by WHO in 2008. It summarizes the
latest data and provides latest estimates of the global
epidemic of multidrug and extensively drug-resistant
tuberculosis (M/XDR-TB). For the first time, this report
includes an assessment of the progress countries
are making to diagnose and treat MDR-TB cases.

link to full text: http://whqlibdoc.who.int/publications/2010/9789241599191_eng.pdf

IU Research Team Discovers TB Disease Mechanism and Molecule to Block It

posted Feb 16, 2010, 7:07 AM by USAID Tuberculosis

Indiana University School of Medicine researchers have identified a mechanism used by the tuberculosis bacterium to evade the body's immune system and have identified a compound that blocks the bacterium's ability to survive in the host, which could lead to new drugs to treat tuberculosis.

[Link to article] Zhong-Yin Zhang, Ph.D., Robert A. Harris Professor and chairman of the Department of Biochemistry and Molecular Biology, and his colleagues revealed the biochemical processes that TB bacteria employ to subvert macrophages – key infection-fighting cells – in this week's online early edition of the Proceedings of the National Academy of Sciences. They also described a compound they have synthesized – I-A09 – that blocked the TB bacterium's activity in laboratory tests.

About one-third of the world's population is infected with TB, a contagious disease that causes nearly 2 million deaths annually, according to the Centers for Disease Control and Prevention. Although medicines to treat TB are available, they must be taken for at least six months to fully eliminate all TB bacteria from the body. People who do not follow the lengthy treatment regimen can become sick and infectious with a more virulent form of the disease that is resistant to standard medicines.

The compound synthesized by the IU group is a proof of concept that a small molecule drug targeted against an essential virulent factor of the TB bacterium can be an effective strategy, Zhang said. If it can be developed into an approved drug, the result could significantly shorten treatment times for TB, he said.

The focus of the research was TB actions inside macrophages, which are infection fighting cells in the body's immune system. Macrophage cells' tools include the production of special proteins called cytokines to attack foreign invaders. Infected macrophages can also initiate a self-destruction mechanism called apoptosis, which signals other immune system cells to mount a defense against the infection.

TB bacteria are able to disable the macrophage defenses by secreting virulent factors into the host. The IU team found that the actions of a particular virulent factor – a protein phosphatase enzyme called mPTPB – blocked both the production of the infection-fighting cytokines, and the macrophage's self-destruct system.

Using combinatorial chemical synthesis and high-throughput screening, the researchers developed the I-A09 compound, which successfully blocked the action of mPTPB. Tests involving live TB bacteria were conducted at the Institute of Tuberculosis Research, University of Illinois at Chicago.

Currently, compound I-A09 is being evaluated in a TB animal model at the Johns Hopkins University School of Public Health. More potent forms of the I-A09 compound are being pursued by the IU team for possible future clinical testing, Dr. Zhang said.

First European reference laboratory network for tuberculosis launched

posted Jan 27, 2010, 1:22 PM by USAID Tuberculosis

25 Jan 2010

ECDC hosted the launch of the European Reference Laboratory Network for Tuberculosis (ERLN-TB) on 25 January 2010 at its first annual meeting in Stockholm, Sweden. Reference laboratories representatives from EU/EEA Member States and candidate countries will engage in an unprecedented initiative in the field of tuberculosis control in the EU. Recognising laboratory function as one of the pillars of optimal tuberculosis control, the network will aim at strengthening the diagnosis of the disease at EU level, in line with the objectives of the Framework action plan to fight tuberculosis in the European Union. Under ECDC coordination, the ERLN-TB will pursue concerted action in capacity building, quality assurance, scientific advice and support.

More information
The added value of a European Union tuberculosis reference laboratory network (Eurosurveillance, Volume 13, Issue 12, 18 March 2008)

ECDC tuberculosis programme: Main activities and coordination of laboratory network and projects

First Case of Highly Drug-Resistant TB Found in US

posted Jan 6, 2010, 5:18 PM by USAID Tuberculosis   [ updated Jan 6, 2010, 5:27 PM ]

This Oct. 5, 2009 photo shows an unidentified tuberculosis and HIV patient on his bed at Wat Prabat Nampu in Lopburi, Thailand. Simple TB is simple to treat, a $10 course of medication, but the pills must be taken in specific combinations for six months to completely wipe out the bacteria. If treatment is stopped short, the TB learns to fight back against the drugs, mutating into a tougher strain for which few, if any, medications exist. (David Longstreath/AP Photo)
Associated Press

First case of extremely drug-resistant TB found in US, other killer diseases return

It started with a cough, an autumn hack that refused to go away.

Then came the fevers. They bathed and chilled the skinny frame of Oswaldo Juarez, a 19-year-old Peruvian visiting to study English. His lungs clattered, his chest tightened and he ached with every gasp. During a wheezing fit at 4 a.m., Juarez felt a warm knot rise from his throat. He ran to the bathroom sink and spewed a mouthful of blood.

I'm dying, he told himself, "because when you cough blood, it's something really bad."

It was really bad, and not just for him.

Doctors say Juarez's incessant hack was a sign of what they have both dreaded and expected for years — this country's first case of a contagious, aggressive, especially drug-resistant form of tuberculosis. The Associated Press learned of his case, which until now has not been made public, as part of a six-month look at the soaring global challenge of drug resistance.

Juarez's strain — so-called extremely drug-resistant (XXDR) TB — has never before been seen in the U.S., according to Dr. David Ashkin, one of the nation's leading experts on tuberculosis. XXDR tuberculosis is so rare that only a handful of other people in the world are thought to have had it.

"He is really the future," Ashkin said. "This is the new class that people are not really talking too much about. These are the ones we really fear because I'm not sure how we treat them."

Forty years ago, the world thought it had conquered TB and any number of other diseases through the new wonder drugs: Antibiotics. U.S. Surgeon General William H. Stewart announced it was "time to close the book on infectious diseases and declare the war against pestilence won."

Today, all the leading killer infectious diseases on the planet — TB, malaria and HIV among them — are mutating at an alarming rate, hitchhiking their way in and out of countries. The reason: Overuse and misuse of the very drugs that were supposed to save us.

Just as the drugs were a manmade solution to dangerous illness, the problem with them is also manmade. It is fueled worldwide by everything from counterfeit drugmakers to the unintended consequences of giving drugs to the poor without properly monitoring their treatment. Here's what the AP found:

— In Cambodia, scientists have confirmed the emergence of a new drug-resistant form of malaria, threatening the only treatment left to fight a disease that already kills 1 million people a year.

— In Africa, new and harder to treat strains of HIV are being detected in about 5 percent of new patients. HIV drug resistance rates have shot up to as high as 30 percent worldwide.

— In the U.S., drug-resistant infections killed more than 65,000 people last year — more than prostate and breast cancer combined. More than 19,000 people died from a staph infection alone that has been eliminated in Norway, where antibiotics are stringently limited.

"Drug resistance is starting to be a very big problem. In the past, people stopped worrying about TB and it came roaring back. We need to make sure that doesn't happen again," said Dr. Thomas Frieden, director of the U.S. Centers for Disease Control and Prevention, who was himself infected with tuberculosis while caring for drug-resistant patients at a New York clinic in the early '90s. "We are all connected by the air we breathe, and that is why this must be everyone's problem."

This April, the World Health Organization sounded alarms by holding its first drug-resistant TB conference in Beijing. The message was clear — the disease has already spread to all continents and is increasing rapidly. Even worse, WHO estimates only 1 percent of resistant patients received appropriate treatment last year.

"We have seen a huge upburst in resistance," said CDC epidemiologist Dr. Laurie Hicks.


Juarez' strain of TB puzzled doctors. He had never had TB before. Where did he pick it up? Had he passed it on? And could they stop it before it killed him?

At first, mainstream doctors tried to treat him. But the disease had already gnawed a golf-ball-sized hole into his right lung.

TB germs can float in the air for hours, especially in tight places with little sunlight or fresh air. So every time Juarez coughed, sneezed, laughed or talked, he could spread the deadly germs to others.

"You feel like you're killing somebody, like you could kill a lot of people. That was the worst part," he said.

Tuberculosis is the top single infectious killer of adults worldwide, and it lies dormant in one in three people, according to WHO. Of those, 10 percent will develop active TB, and about 2 million people a year will die from it.

Simple TB is simple to treat — as cheap as a $10 course of medication for six to nine months. But if treatment is stopped short, the bacteria fight back and mutate into a tougher strain. It can cost $100,000 a year or more to cure drug-resistant TB, which is described as multi-drug-resistant (MDR), extensively drug-resistant (XDR) and XXDR.

There are now about 500,000 cases of MDR tuberculosis a year worldwide. XDR tuberculosis killed 52 of the first 53 people diagnosed with it in South Africa three years ago.

Drug-resistant TB is a "time bomb," said Dr. Masae Kawamura, who heads the Francis J. Curry National Tuberculosis Center in San Francisco, "a manmade problem that is costly, deadly, debilitating, and the biggest threat to our current TB control strategies."

Juarez underwent three months of futile treatment in a Fort Lauderdale hospital. Then in December 2007 he was sent to A.G. Holley State Hospital, a 60-year-old massive building of brown concrete surrounded by a chain-link fence, just south of West Palm Beach.

"They told me my treatment was going to be two years, and I have only one chance at life," Juarez said. "They told me if I went to Peru, I'm probably going to live one month and then I'm going to die."

Holley is the nation's last-standing TB sanitarium, a quarantine hospital that is now managing new and virulent forms of the disease.

Tuberculosis has been detected in the spine of a 4,400-year-old Egyptian mummy. In the 1600s, it was known as the great white plague because it turned patients pale. In later centuries, as it ate through bodies, they called it "consumption." By 1850, an estimated 25 percent of Europeans and Americans were dying of tuberculosis, often in isolated sanatoriums like Holley where they were sent for rest and nutrition.

Then in 1944 a critically ill TB patient was given a new miracle antibiotic and immediately recovered. New drugs quickly followed. They worked so well that by the 1970s in the U.S., it was assumed the disease was a problem of the past.

Once public health officials decided TB was gone, the disease was increasingly missed or misdiagnosed. And without public funding, it made a comeback among the poor. Then immigration and travel flourished, breaking down invisible walls that had contained TB.

Drug resistance emerged worldwide. Doctors treated TB with the wrong drug combinations. Clinics ran out of drug stocks. And patients cut their treatment short when they felt better, or even shared pills with other family members.

There are two ways to get drug resistant TB. Most cases develop from taking medication inappropriately. But it can also be transmitted like simple TB, a cough or a sneeze.

In the 1980s, HIV and AIDS brought an even bigger resurgence of TB cases. TB remains the biggest killer of HIV patients today.

For decades, drug makers failed to develop new medicines for TB because the profits weren't there. With the emergence of resistant TB, several private drug companies have started developing new treatments, but getting an entire regimen on the market could take 24 years. In the meantime, WHO estimates each victim will infect an average of 10 to 15 others annually before they die.

A.G. Holley was back in business.


Holley's corridors are long and dark, with fluorescent tubes throwing harsh white light on drab walls. One room is filled with hulking machines once used to collapse lungs, sometimes by inserting ping pong balls. Antique cabinets hold metal tools for spreading and removing ribs — all from a time when TB was rampant and the hospital's 500 beds were filled.

Only 50 beds are funded today, but those are mostly full. More than half the patients are court-ordered into treatment after refusing to take their meds on the outside.

Juarez came voluntarily. In the beginning, he was isolated and forced to wear a mask when he left his room. He could touch his Peruvian family only in pictures taped to the wall. He missed his dad, his siblings, his dog, his parrot, and especially his mother.

"I was very depressed," he said. "I had all this stuff in my mind."

He spent countless hours alone inside the sterile corner room reserved for patients on extended stays — dubbed "the penthouse" because it is bigger and lined by a wall of windows.

His moods ran hot and cold. He punched holes in the walls out of frustration, played loud reggaeton music with a thumping beat and got into fights with other patients. He covered his door's small window with a drawing of an evil clown to keep nurses from peering inside. He made friends with new patients, but was forced to stay long after many of them came, got cured, and left.

Early on, Juarez's treatment was similar to chemotherapy. Drugs were pumped into his bloodstream intravenously three times a day, and he choked down another 30 pills, including some that turned his skin a dark shade of brown. He swallowed them with spoonfuls of applesauce, yogurt, sherbet and chocolate pudding, but once they hit his stomach, waves of nausea sometimes sent him heaving. He would then have to force them all down again.

"When he first came in we really had to throw everything and the kitchen sink at him," said Ashkin, the hospital's medical director, who experimented on Juarez with high doses of drugs, some not typically used for TB. "It was definitely cutting edge and definitely somewhat risky because it's not like I can go to the textbooks or ... journal articles to find out how to do this."

After 17 years of handling complex cases — including TB in the brain and spine — Ashkin had never seen a case so resistant. He believed he would have to remove part of Juarez's lung.

Ashkin dialed Peru to talk to the young man's father.

It's a rare disease, said Ashkin, hard to define. Your son is one of two people in the world known to have had this strain, he said.

"What happened to the other person?" his father asked.

"He died."


Juarez's adventure in the U.S. had turned into a medical nightmare.

About 60 million people visit the U.S. every year, and most are not screened for TB before arrival. Only refugees and those coming as immigrants are checked. The top category of multidrug-resistant patients in the U.S. — 82 percent of the cases identified in 2007 — was foreign-born patients, according to the CDC.

The results are startling among those tested, said Dr. Angel Contreras, who screens Dominicans seeking to enter the U.S. on immigrant visas. The high rate of MDR-TB in the Dominican Republic coupled with high HIV rates in neighboring Haiti are a health crisis in the making, he said.

"They're perfect ingredients for a disaster," he said.

Juarez's homeland, Peru, is also a hotspot for multidrug-resistant TB. DNA fingerprinting linked his disease to similar strains found there and in China, but none with the same level of resistance.

"So the question is: Is this a strain that's evolving? That's mutating? That's becoming more and more resistant?" asked Ashkin. "I think the answer is yes."

Doctors grappling with these new strains inadvertently give the wrong medicines, and so the TB mutates to become more aggressive and resistant.

Poor countries also do not have the resources to determine whether a patient's TB is drug-resistant. That requires sputum culturing and drug-susceptibility testing — timely, expensive processes that must be performed in capable labs. WHO is working to make these methods more available in high-risk countries as well as negotiating cheaper prices for second-line drugs.

"There's a lot of MDR and XDR-TB that hasn't been diagnosed in places like South Africa and Peru, Russia, Estonia, Latvia," said Dr. Megan Murray, a tuberculosis expert at Harvard. "We think it's a big public health threat."

Experts argue if wealthy countries do not help the worst-hit places develop comprehensive TB programs, it puts everyone at risk.

"You're really looking at a global issue,'" said Dr. Lee Reichman, a TB expert at the New Jersey Medical School Global Tuberculosis Institute. "It's not a foreign problem, you can't keep these TB patients out. It's time people realize that."


Juarez spent a year and a half living alone in a room plastered with bikini-clad blondes, baseball caps and a poster of Mt. Everest for inspiration. There were days when he simply shut down and refused his meds until his family convinced him to keep fighting.

"I was thinking that maybe if I need to die, then that's what I need to do," he said, perched on his bed in baggy jeans. "I felt like: 'I'm never going to get better. I'm never going to get out of here.'"

When put side by side, his CAT scans from before and after treatment are hard to believe. The dark hole is gone, and only a small white scar tattoos his lung.

"They told me the TB is gone, but I know that TB, it doesn't have a cure. It only has a treatment like HIV," he said, his English now fluent and his body weight up 32 pounds from when he first arrived. "The TB can come back. I saw people who came back to the hospital twice and some of them died. So, it's very scary."

His treatment cost Florida taxpayers an estimated $500,000, a price tag medical director Ashkin says seems like an astronomical amount to spend on someone who's not an American citizen. But he questions how the world can afford not to treat Juarez and others sick with similar lethal strains.

"This is an airborne spread disease ... so when we treat that individual, we're actually treating and protecting all of us," he said. "This is true homeland security."

In July, at age 21 — 19 months after checking in — Juarez swallowed his last pills, packed a few small suitcases and wheeled them down the hospital's long corridor.

The last time doctors saw him, he was walking out of the sanitarium into south Florida's soupy heat.


Martha Mendoza is an AP national writer based in Mexico City. Margie Mason is an AP medical writer who worked on this project as a 2009 Nieman Global Health Fellow with The Nieman Foundation at Harvard University.

One third of world's population has tuberculosis bacterium

posted Jan 6, 2010, 5:14 PM by USAID Tuberculosis

1/6/2010 Reuters
More than two billion people, or a third of the world's total population, are infected with Mycobacterium tuberculosis, the bacteria that causes tuberculosis (TB).

Tuberculosis is the world's seventh-leading cause of death. It killed 1.8 million people worldwide last year, up from 1.77 million in 2007. It is one of three primary diseases that are closely linked to poverty, the other two being Aids and malaria.

Some facts about tuberculosis:

* It is spread easily through the air. When infectious people cough, sneeze, talk or spit, they expel the bacteria. Just a small amount is enough for transmission. Someone in the world is newly infected with TB every second.

* Nearly all TB infections are latent, with carriers showing no symptoms and they are not infectious. However, one in 10 will become sick with active TB in his or her lifetime due primarily to a weakened immune system.

* Of the 1.8 million deaths in 2008, or 4,930 deaths a day, half a million were Aids patients. TB affects mostly young adults in their most productive years. The vast majority of TB deaths are in the developing world. More than half occur in Asia.

* The World Health Organization estimates that 9.4 million people developed active TB in 2008, up from 9.27 million in 2007 and 9.24 million in 2006. Among the 15 countries with the highest TB incidence rates in 2007, 13 were in Africa, while half of all new cases were in six Asian countries - Bangladesh, China, India, Indonesia, Pakistan and the Philippines.

* TB is the seventh-highest cause of mortality in poor countries.

* The average TB patient loses three to four months of work and up to 30 per cent of yearly household earnings. The World Bank estimates that the disease diminishes 4 per cent to 7 per cent of GDP in some of the worst-affected countries.

* Drug-resistant TB is caused by inconsistent or partial treatment often because patients stop taking their medication because they start to feel better.

* A particularly dangerous form of TB is multidrug-resistant TB (MDR-TB), which is TB that resists at least isoniazid and rifampicin, the two most powerful anti-TB drugs.

* Rates of MDR-TB are high in some countries, especially in India, China and the former Soviet Union, and threaten TB control efforts. MDR-TB is present in virtually all countries surveyed by the World Health Organisation.

* Extensively drug-resistant TB, or XDR-TB, is a relatively rare type of TB. Between 35 per cent and 50 per cent of patients with this form of TB die.

Sources: WHO, US Centers for Disease Prevention and Control, The Lancet series on Health System Reform in China, 2009.

WHO: 6 million people with TB cured

posted Dec 7, 2009, 5:02 AM by USAID Tuberculosis   [ updated Dec 9, 2009, 4:26 PM ]

8 December 2009 -- Some 36 million people have been cured of TB over the past 15 years through a rigorous approach to treatment endorsed by WHO. New data, released today by WHO, also indicate that up to 8 million TB deaths have been averted. Read the full text document at the WHO Website

1-8 of 8